ERBB2 and breast carcinoma: Human epidermal growth factor receptor 2 metabolomics studies, also known as ERBB2-positive breast cancer, have shown that patients who responded well to trastuzumab-paclitaxel neoadjuvant therapy had higher levels of serum SPD than those who responded poorly, and lower levels of tryptophan [79].